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Introduction
Acute esophageal variceal bleeding (EVB) is a severe
complication of portal hypertension, with a mortality
rate ranging from 30% to 50%.1 A large number of
studies have been published on the management of
acute EVB. Vasoactive drugs are often considered as
the first-line therapy for acute EVB because they are
effective and easy to use. Among the vasoactive drugs,
somatostatin (SMT) produces a significant and
sustained decrease in the hepatic venous pressure
gradient.2 It could control acute EVB in 60–80% of
cases.3
The optimal timing of endoscopic treatment
for acute EVB remains undetermined.4 It has been
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suggested that endoscopic therapies should be the
first choice of treatment for acute EVB and that
success in control of bleeding could be achieved in 80–
90% of cases.4,5 Several studies have shown emergency
sclerotherapy and vasoactive drugs to have similar
efficacy of hemostasis.6–8 However, a recent meta-
analysis found that vasoactive drugs were as effective as
emergency sclerotherapy, but sclerotherapy carried an
increased risk of adverse effects.9 It was concluded that
the available evidence did not support emergency
sclerotherapy as first-line treatment when compared
with vasoactive drugs, and endoscopic treatment might
be limited to pharmacologic treatment failure.
Endoscopic variceal l igation (EVL) and
sclerotherapy are both effective endoscopic therapies
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for acute EVB.10 EVL is replacing sclerotherapy because
it has fewer complications than sclerotherapy and
decreases the early rebleeding rate.5,11,12 Our previous
trial found that EVL was superior to sclerotherapy in
the control of active EVB.13 Emergency EVL was also
recommended in the UK guidelines as the treatment
of choice for acute EVB,14 whereas some experts still
favor using vasoactive drugs as first-line therapy.
Although emergency EVL and SMT are often used
in the treatment of acute EVB, no study has compared
the efficacy of these 2 therapies.3,9,10 We conducted
this trial to test the hypothesis that emergency EVL is
better at controlling acute EVB than SMT. We also
compared the adverse effects and survival of both
treatments.
Methods
Patients presenting with acute EVB were considered
for enrollment in the study. The inclusion criteria were
the following: (1) a history of cirrhosis; (2) acute EVB
presenting with hematemesis, melena, or both; (3)
hospital arrival within 12 hours after onset of the
symptoms; (4) no use of vasoactive drugs or endoscopic
therapy before referral to our hospital; and (5) age
between 20 and 75 years. Patients with the following
conditions were excluded: (1) a Child-Pugh score
greater than 12 points; (2) hepatorenal syndrome or
uremia; (3) comatous status; (4) hepatocellular
carcinoma or other malignancy; (5) portal vein
thrombosis; (6) sclerotherapy or banding ligation
within 3 months; (7) use of `-blocker within 1 week;
(8) previous surgical or transjugular intrahepatic
portosystemic stent shunt; and (9) refusal to participate
in the study. After resuscitation and adequate
transfusion, emergency endoscopy was performed
within 12 hours after the patient’s arrival at the hospital.
Eligible patients were randomized into the emergency
EVL group or SMT group. The endpoint of this study
was failure to control acute EVB within 48 hours.
Randomization of patients
Patients were immediately randomized to receive
emergency EVL or SMT infusion during the emergency
endoscopy. A statistician created sequentially numbered
opaque and sealed envelopes containing a digit (1 for
the emergency EVL group and 2 for the SMT group)
derived from computer-generated random numbers.
The investigators opened the envelopes and assigned
the patients to the designated groups. This protocol
was approved by the Medical Ethics Committee of the
hospital. All patients and their next of kin understood
the treatment protocol and gave their consent before
the emergency endoscopy.
Emergency EVL
Patients randomized to the emergency EVL group
underwent EVL immediately after initial endoscopic
examination. Emergency EVL was performed by 3
experienced endoscopists who had performed at least
200 cases of EVL prior to this study. The ligation
procedure included the use of an overtube, a
pneumoactive ligation device (Sumitomo Bakelite Co.,
Ltd, Tokyo, Japan), and an Olympus XQ-230
videoendoscope (Olympus Optical Co., Ltd, Tokyo,
Japan). The varices were ligated with 4–8 rubber
bands from the gastroesophageal junction and the
stigmata of recent bleeding, such as a white nipple sign
or active bleeding site, if present. Patients were allowed
to start a liquid diet for 3 days and normal or low-salt
diet subsequently if they did not encounter treatment
failure within 48 hours.
SMT infusion
Patients randomized to the SMT group received an
initial bolus of 250 +g SMT during the emergency
endoscopy when the diagnosis of acute EVB was
established. A continuous infusion of SMT maintained
at 250 +g/hour was used for the next 48 hours. A
nasogastric tube was inserted soon after endoscopic
examination. Gastric lavage was performed at 4-hour
intervals to monitor the efficacy of hemostasis. If the
aspirated content became clear persistently for 24
hours, the nasogastric tube was removed. If acute EVB
was controlled, patients underwent elective EVL at 48
hours after randomization. Patients were then allowed
to take a liquid diet for 3 days and normal or low-salt
diet subsequently. If a bolus of SMT failed to control
bleeding in patients with active bleeding during
emergency endoscopy, alternative treatments,
including a balloon tamponade using a Minnesota
tube, EVL, and transjugular intrahepatic portosystemic
stent shunt with or without the combination of SMT
infusion, were offered to the patients according to
their choice or that of their next of kin.
General care of patients
Patients were resuscitated and transfused with packed
red cells, whole blood, and fresh frozen plasma during
the study period, aiming at maintaining hematocrit
between 27% and 30%. The pulse rate, blood pressure,
and urine output were closely monitored. Patients
were given oral lactulose for 2 weeks to prevent hepatic
encephalopathy. Patients also received oral sucralfate
after EVL to enhance the healing of ligation-induced
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esophageal ulcers. Prophylactic intravenous cefazolin
(1 g every 6 hours) was administered for 3 days after
randomization to prevent possible concomitant
infection and this prescription was changed according
to the results of bacterial cultures if frank infection
occurred. If emergency EVL or SMT failed to control
acute EVB, alternative treatments, including a balloon
tamponade using a Minnesota tube, repeated EVL,
and transjugular intrahepatic portosystemic stent shunt
with or without the combination of SMT infusion,
were offered to the patients. Adverse effects associated
with emergency EVL and SMT were prospectively
recorded and categorized into major or minor adverse
effects. All patients who survived the acute EVB episode
were enrolled into an ongoing trial comparing oral
nadolol plus isosorbide-5-mononitrate and repeated
sessions of EVL to prevent recurrent variceal bleeding
and were discharged from the hospital 2 days later.
Definitions
Acute EVB was defined as bleeding from an esophageal
varix at the time of endoscopy or the presence of large
varices with blood in the stomach and no other
recognizable cause of bleeding.14 The severity of
esophageal varices was graded based on Beppu et al’s15
system. Active bleeding was defined as oozing or
spurting seen on endoscopy. Hypovolemic shock was
defined as a pulse rate higher than 120 beats per minute
or systolic blood pressure lower than 80 mmHg. The
definition of treatment failure of acute EVB followed
the Baveno II consensus.16 Successful treatment was
defined as absence of treatment failure and survival
during the 48-hour study period. Any new hematemesis
or melena after 48 hours from randomization was
defined as the first rebleeding episode.
Sample size calculation
The expected efficacy of SMT infusion in controlling
acute EVB was approximately 70%.6 The corresponding
figure for emergency EVL was approximately 90%
according to our experience.13 The sample size needed
to detect significant differences of hemostatic efficacy
was calculated as 62 patients in each group using a
2-sided test with 80% power at a significance level of 5%.
Statistical analysis
Clinical data were reported as means ( SD. Continuous
variables of both groups were compared with the
independent Student t-test or the nonparametric
Mann-Whitney rank sum test for unpaired data.
Categorical variables were compared using the Chi-
square test or Fisher’s exact test when appropriate.
Stepwise Cox regression analysis was used to examine
the independent predictors for treatment failure and
42-day mortality. The actuarial survival curves of both
groups were constructed using the Kaplan-Meier
method and compared with a log-rank test. The SPSS
statistical package (SPSS 10.0; SPSS, Inc., Chicago,
IL, USA) was used. A p value of less than 0.05 was
considered statistically significant.
Results
A total of 296 patients with acute EVB were recruited
from August 2000 through May 2004. One hundred
and seventy-one patients were excluded because of
banding ligation within 3 months (38 patients), use of
`-blocker within 1 week prior to the EVB episode
(37 patients), a Child-Pugh score greater than 12
points (20 patients), uremia (5 patients), hepatocellular
carcinoma (57 patients), cholangiocarcinoma
(2 patients), breast cancer (1 patient), colon cancer
(2 patients), pancreatic cancer (1 patient), laryngeal
cancer (1 patient), previous transjugular intrahepatic
portosystemic stent shunt (2 patients), and refusal to
participate in the study (5 patients) (Figure 1). The
eligible 125 patients were entered into the study and
randomized to the emergency EVL group (62 patients)
and SMT group (63 patients). The demographic,
clinical, and laboratory features of the included patients
are presented in Table 1. The age, gender, etiologies
and severity of cirrhosis, the severity of esophageal
varices, numbers of active bleeders, concomitant gastric
varices, a history of previous variceal hemorrhage,
hematocrit, serum glucose level, renal function,
transfusion before randomization, and numbers of
patients with infection were not significantly different
between the 2 groups. The time elapsed from admission
to diagnostic endoscopy was 6.9 ( 4.3 hours in the
emergency EVL group and 7.0 ( 4.4 hours in the SMT
group (p = 0.9).
Treatment failure
Of the 62 patients undergoing emergency EVL, 3
(4.8%) experienced treatment failure (Table 2). Two
patients received repeated emergency EVL and 1
received a balloon tamponade with subsequent EVL
for treatment failure. Of the 63 SMT group patients,
20 (31.7%) encountered treatment failure. For the
treatment failure patients, 13 received emergency
EVL and 7 received a balloon tamponade and
subsequent EVL. Patients in the SMT group had a
significantly higher proportion of treatment failure
than patients in the emergency EVL group (p =
0.0001, Figure 2). Of the subgroup of patients who
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had active bleeding at the initial endoscopy, patients in
the SMT group had a higher rate of treatment failure
than emergency EVL group patients (69.2% vs 11.8%,
p = 0.002). Of the subgroup of nonactive-bleeding
patients at the initial endoscopy, the proportion of
treatment failure was also higher in the SMT group
than in the emergency EVL group (22.0% vs 2.2%,
p = 0.004). Univariate analysis by Cox regression
showed that SMT infusion (relative risk, 6.4; 95%
confidence interval [CI], 1.9–21.9; p = 0.003) and
active bleeding at initial endoscopy (relative risk, 2.8;
95% CI, 1.1–6.9; p = 0.03) were associated with
treatment failure. SMT infusion (relative risk, 6.7; 95%
CI, 1.9–23.6; p = 0.003) and active bleeding (relative
risk, 3.1; 95% CI, 1.2–8.0; p = 0.02) were found to be
independent predisposing factors of treatment failure
by multivariate analysis using stepwise Cox regression.
Emergency EVL group patients had significantly
fewer requirements for transfusion during the admission
period than SMT group patients (4.7 ( 3.2 vs 6.9 ( 7.3
units, p = 0.03; Table 2). Patients in the emergency
EVL group also had a trend toward shorter hospital
stay when compared with patients in the SMT group
(7.7 ( 4.0 vs 10.2 ( 9.9 days, p = 0.07).
Table 1. Clinical characteristics of patients randomized to receive emergency endoscopic variceal ligation (EVL) and
somatostatin (SMT) infusion
EVL group SMT group p value
(n = 62) (n = 63)
Age, yr 54.5 ( 12.8 51.8 ( 15.2 0.3
Sex, male/female 43/19 52/11 0.1
Etiology of cirrhosis
HBV/HCV/alcohol/other 11/19/24/8 15/14/29/5 0.5
Hematocrit, % 25.6 ( 7.1 26.3 ( 7.0 0.6
Serum albumin, g/dL 2.9 ( 0.5 3.0 (  0.5 0.5
Serum bilirubin, mg/dL 3.0 ( 4.1 3.0 (  2.8 0.9
Ascites 34 33 0.8
Prothrombin time-prolonged, sec 2.3 ( 2.4 2.3 (  2.3 0.9
Encephalopathy 15 19 0.5
Child-Pugh class, A/B/C 13/31/18 18/27/18 0.6
Child-Pugh score 8.3 ( 2.0 8.3 (  2.3 0.9
Serum creatinine, mg/dL 1.1 ( 0.7 1.2 (  0.6 0.9
Serum glucose, mg/dL 171.2 ( 100.7 211.1 ( 132.6 0.06
Diabetes 20 22 0.8
Hypovolemic shock 8 13 0.3
Active bleeding at endoscopy 17 13 0.4
Variceal size, F1/F2/F3 5/38/19 2/41/20 0.5
Presence of gastric varices 22 21 0.8
Transfusion before randomization, units 4.1 ( 2.7 4.6 (  3.7 0.4
Infection 6 7 0.7
Previous episode of variceal bleeding 14 15 0.9
HBV =  viral hepatitis B; HCV =  viral hepatitis C.
Figure 1. The CONSORT diagram showing the flow of participants
through each stage of this study.
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Rebleeding
After control of acute EVB, 37 patients in the
emergency EVL group underwent repeated EVL and
the other 25 patients received nadolol plus isosorbide-
5-mononitrate to prevent recurrent EVB. Four
patients (6.4%) experienced rebleeding within 42
days, which was controlled by EVL. Of the patients
in the SMT group, 35 underwent repeated EVL and
28 received nadolol plus isosorbide-5-mononitrate
to prevent rebleeding. Seven patients (11.1%)
experienced rebleeding within 42 days, which was
controlled by EVL, except for 1 patient who underwent
transjugular intrahepatic portosystemic stent shunt
creation because of uncontrolled rebleeding. There
was no significant difference in the modalities used
to prevent rebleeding and the rebleeding episodes
between the emergency EVL group and the SMT
group.
Table 2. Results of treatment
EVL group SMT group p value
(n = 62) (n = 63)
Treatment failure
Overall 3 20 0.0001
Active-bleeding patients 2 9 0.002
Nonactive-bleeding patients 1 11 0.004
Total transfusion, units 4.7 ( 3.2 6.9 ( 7.3 0.03
Serum glucose at 48 hours, mg/dL 156.9 ( 88.2 179.3 ( 103.5 0.4
Hospital stay, d 7.7 ( 4.0 10.2 ( 9.9 0.07
Rebleeding 4 3 0.7
EVL = endoscopic variceal ligation; SMT = somatostatin.
Figure 2. Cumulative probability of patients remaining free of
treatment failure during 48 hours. Patients undergoing emergency
endoscopic variceal ligation had a significantly higher proportion
free of treatment failure at 48 hours than patients receiving
somatostatin infusion (95.2% vs 68.3%, p = 0.0001). EVL =
endoscopic variceal ligation; SMT = somatostatin.
Table 3. Adverse effects of patients receiving emergency
endoscopic variceal ligation (EVL) and somatostatin (SMT)
infusion during 48 hours
EVL group SMT group
Total episodes 20 27
Mild adverse effects 18 23
Chest pain 7 0
Odynophagia 5 1
Epigastralgia 1 2
Abdominal fullness 2 0
Abdominal cramps 1 3
Nausea and vomiting 2 5
Hyperglycemia – 12
Severe adverse effects 2 4
Aspiration pneumonia 1 2
Sepsis 1 1
Hyperosmolar nonketotic coma – 1
Adverse effects
In total, 20 episodes of adverse effects were found in the
emergency EVL group within 48 hours (Table 3). Chest
pain and odynophagia were the most common mild
adverse effects. Two episodes of severe adverse effects,
including aspiration pneumonia and sepsis, were found
in each of the patient groups. Patients in the SMT group
had 27 episodes of adverse effects. Hyperglycemia and
nausea accounted for most of the mild adverse effects.
Four episodes of severe adverse effects, including
aspiration pneumonia (2 episodes), sepsis (1 episode),
and hyperosmolar nonketotic coma (1 episode), were
found. The total incidences of adverse effects were not
significantly different between the 2 groups (p = 0.2).
Survival
The 42-day mortality rates were 5 patients (8.1%) in
the emergency EVL group and 3 patients (4.8%) in
0
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the SMT group (p = 0.5, Figure 3). No mortality
within 48 hours was found in either of the groups.
The Child-Pugh scores of the mortality patients in
the emergency EVL group were 11 points in 4
patients and 12 points in 1 patient. The Child-Pugh
scores of the mortality patients in the SMT group
were 11 points in 1 patient and 12 points in
2 patients. The causes of mortality are shown in
Table 4. Only 1 patient in the emergency EVL group
died of uncontrolled variceal bleeding, at day 30.
Univariate analysis by Cox regression showed that
active bleeders at initial endoscopy (relative risk,
5.5; 95% CI, 1.3–23.2; p = 0.02) and Child-Pugh
score (relative risk, 2.2; 95% CI, 1.5–3.1; p < 0.001)
were predictors for 42-day mortality. Multivariate
analysis by stepwise Cox regression found that
Child-Pugh score was the only independent predictor
for 42-day mortality (relative risk, 2.2; 95% CI,
1.5–3.1; p < 0.001).
Discussion
The present study confirmed our hypothesis that
emergency EVL had an advantage over SMT in the
control of acute EVB, both in the active bleeders and
the nonactive bleeders. Patients in the emergency
EVL group had fewer requirements for transfusion
than patients in the SMT group because of fewer
episodes of treatment failure. Additionally, patients
undergoing emergency EVL had a trend toward shorter
hospital stay compared with patients receiving SMT
infusion because EVL was used early.
The high success rate of emergency EVL in
controlling acute EVB was consistent with previous
trials.11–13 Two possibilities may account for the higher
hemostasis rate by emergency EVL than SMT. First,
hemostasis by EVL is achieved by mechanical
strangulation of the varix at or near the bleeding site
and probably results in a more sustained efficacy of
hemostasis. On the contrary, SMT decreases portal
pressure and achieves hemostasis by inhibiting
glucagon and gastrointestinal vasodilatory peptides.3
A decrease of hepatic venous pressure gradient greater
than 10% from the baseline was found in only 60% of
bleeding patients using SMT.2 The difference in
treatment failure rates between SMT and emergency
EVL in this trial was more marked for active-bleeding
patients (69.2% vs 11.8%). Second, emergency EVL
offers a definitive treatment in addition to achieving
initial hemostasis, but the hemostasis by SMT is
usually not durable and patients require subsequent
endoscopic therapies or portal hypotensive drugs. It
was noteworthy that a nasogastric tube was used in
the SMT group after emergency endoscopy but not
in the EVL group because insertion of a nasogastric
tube was inappropriate in the patients who had just
received EVL. The  absence of the use of a nasogastric
tube in the EVL group may lead to a potential
underestimation of the rebleeding rate. Besides, SMT
was started when acute EVB was found during an
emergency endoscopy in the SMT group patients. It
was possible that the time lag of drug therapy decreased
the efficacy of SMT.
The episodes of adverse effects were comparable
between the emergency EVL group and the SMT
group in this trial. Chest pain and hyperglycemia were
the most common mild adverse effects of emergency
EVL and SMT infusion, respectively. Few severe adverse
effects were associated with both therapies.
Interestingly, sepsis and hyperosmolar nonketotic coma
occurred in a diabetic patient  in the SMT group.
Whether SMT was involved in the development of
hyperosmolar nonketotic coma in this case was not
Table 4. Mortality of patients undergoing emergency
endoscopic variceal ligation (EVL) and somatostatin (SMT)
infusion for acute esophageal variceal bleeding
EVL group SMT group
Mortality within 42 days 5 3
Causes of mortality
Variceal bleeding 1 0
Liver failure 2 0
Aspiration pneumonia 1 2
Sepsis 1 1
Figure 3. Cumulative survival of patients undergoing emergency
endoscopic variceal ligation and receiving somatostatin infusion.
There was no significant difference in survival between the
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known. However, close monitoring of the serum
glucose level during the administration of SMT,
especially in patients with diabetes, may be necessary,
because bacterial infection is frequently seen in cirrhotic
patients with gastrointestinal bleeding.17
The advancement of therapy for acute EVB has
improved the survival of cirrhotic patients.18,19 The 42-
day mortality rate was recently estimated to be about
20%.20 The 42-day mortality rates of our patients
(8.1% for the emergency EVL group and 4.8% for the
SMT group) were comparable with those of a study
investigating sclerotherapy and SMT (8.9% for each
arm).7 Although more patients in the SMT group
encountered treatment failure, no patient died of
variceal bleeding because of effective rescue EVL or a
balloon tamponade with subsequent EVL. In fact, we
found that a high Child-Pugh score was the only
independent predictor for mortality. The low mortality
rates in our patients may be due to the enrollment of
patients with a Child-Pugh score equal to or less than
12 points, the exclusion of patients with hepatocellular
carcinoma (a confounding factor for controlling acute
EVB), and the routine use of antibiotics that improve
survival in an acute EVB episode.17 Nevertheless, it
should be recognized that the 42-day mortality rate, as
well as the 42-day rebleeding rate, was not the primary
endpoint of this study, although the later interventions
in the prevention of rebleeding were not significantly
different in either group.
Although the current study showed that early EVL
was beneficial for variceal bleeding patients, the high
efficacy of emergency EVL does not necessarily discard
the use of vasoactive drugs. Early administration of
vasoactive drugs may improve the efficacy of therapeutic
endoscopy and reduce the rate of treatment failure.21
It was, therefore, suggested in Baveno III that vasoactive
drugs should be started as soon as possible before
diagnostic endoscopy.22 Vasoactive drugs were not
used prior to diagnostic endoscopy in this trial because
the study was designed just before the consensus was
reached, and this may raise critical concerns.
Nevertheless, all the patients were properly managed
before randomization and effective treatments were
used immediately once the diagnosis of acute EVB was
established. Alternative therapies were offered to the
SMT group patients if a bolus of SMT failed to control
active bleeding. A reasonable strategy is to start
vasoactive drugs at admission with associated endoscopic
therapy at the time of diagnostic endoscopy.20,23
However, EVL combined with a vasoactive drug does
not result in a better survival than EVL alone, although
the combination therapy is more effective than EVL in
the control of acute EVB.24,25 More adverse effects
might be expected with the combination therapy
than vasoactive drugs or endoscopic treatment alone.9
Future randomized controlled trials would be
necessary to compare vasoactive drugs and emergency
EVL with vasoactive drugs to determine the optimal
timing of EVL.
In conclusion, emergency EVL and SMT were
both effective and safe treatments for acute EVB.
Emergency EVL was superior to SMT in terms of
controlling acute EVB, reducing the requirements for
transfusion, and shortening the hospital stay. These
findings suggest that early EVL for patients with acute
EVB is encouraged if endoscopists experienced in
EVL are available.
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